Multiomics Market By Component (Instruments, Consumables and Assay Kits, Software and Cloud Platforms, Databases, Research Services), By Omics Combination (Genomics–Transcriptomics, Proteogenomics, Transcriptomics–Proteomics, Genomics–Metabolomics, Integrated Multi-Layer Analysis), By Research Resolution (Bulk Multiomics, Single-Cell Multiomics, Spatial Multiomics), By Application (Oncology, Immunology, Neurological Disorders, Metabolic Diseases, Cardiovascular Research, Rare Diseases, Drug Discovery, Population Health), By End User (Pharmaceutical and Biotechnology Companies, Academic and Government Research Institutes, Hospitals and Clinical Laboratories, Biobanks, Contract Research Organizations), By Geography, Segment Revenue Estimation, Forecast: 2026–2032

Multiomics Market: Integrated Biological Data Reshapes Precision Research and Drug Discovery

The Global Multiomics Market was valued at USD 3.25 billion in 2025 and is projected to reach USD 8.82 billion by 2032, expanding at a CAGR of 15.3% during 2026–2032, according to internal projections by Strategic Market Research.

 

Multiomics combines information from genomics, transcriptomics, proteomics, metabolomics, epigenomics, and related biological fields. Its commercial value comes from connecting these data layers rather than examining each one separately.

 

Genomic information indicates inherited biological potential, while transcriptomics shows which genes are active. Proteins provide evidence of cellular function, and metabolites reflect the effects of disease, medication, diet, environment, and lifestyle. Combining these layers can help pharmaceutical companies identify stronger drug targets, validate biomarkers, separate patient groups, and understand why apparently similar patients respond differently to treatment.

 

Government funding is helping multiomics move beyond small academic studies. The U.S. National Institutes of Health awarded USD 50.3 million in 2023 to establish the Multi-Omics for Health and Disease consortium. The five-year program includes disease study sites, data-production centers, and a dedicated analysis and coordination center, creating demand for sample processing, research services, software, and data management.

 

Biological Layers Create Distinct Revenue Pools

The human genome contains more than three billion DNA base pairs. Genomics remains the most established component of multiomics because sequencing infrastructure, reference databases, and research workflows are already widely available.

Genomics accounted for an estimated 40.6% of Multiomics Market revenue in 2025, representing approximately USD 1.32 billion based on base-year valuation. The segment’s leadership reflects the extensive use of sequencing systems, consumables, laboratory services, and genomic databases across pharmaceutical companies and research institutions.

Commercial activity is shifting from sequencing individual genomes toward linking genetic variation with medical records, protein expression, environmental exposure, and long-term health outcomes.

Data diversity has also become an important research and purchasing consideration. Genomic studies have historically underrepresented several population groups, limiting the broader relevance of certain biomarkers and disease-risk models.

The NIH All of Us Research Program is helping address this gap. Its initial genomic release included nearly 250,000 participants and identified more than 275 million previously unreported genetic variants. Approximately 77% of participants with genomic data belonged to groups historically underrepresented in biomedical research.

In July 2026, the program reached a new milestone by providing access to data from more than 747,000 participants. The resource now contains over 1.3 billion genetic variants, protein data from nearly 10,000 participants, and RNA data from almost 9,000 individuals. Its expanding scale supports demand for secure research environments, population-specific reference datasets, analytical software, and cloud-based services..

 

Transcriptomics Expands Through Single-Cell and Spatial Research

Transcriptomics measures active gene expression and helps researchers understand how cells respond to disease, treatment, or changes in their surroundings. Demand has moved beyond examining complete tissue samples toward single-cell and spatial systems that distinguish different cell populations within the same tissue.

Tumours contain cancer cells, immune cells, blood vessels, and surrounding tissue, all of which may respond differently to treatment. Spatial and single-cell platforms preserve this biological context, supporting demand for specialised instruments, imaging systems, assay consumables, and analytical software.

 

Proteomics Becomes a Strategic Expansion Area

Proteins are closely connected to disease activity and drug response, making proteomics an important bridge between genetic discovery and therapeutic development.

UK Biobank released information on approximately 3,000 proteins from more than 54,000 participants. Its larger proteomics project intends to measure up to 5,400 proteins across 600,000 samples, including 100,000 repeat samples collected as long as 15 years after the original sample.

These long-term measurements can support research into disease progression, treatment response, and early biological changes. Large-scale adoption benefits providers of protein panels, laboratory instruments, sample-processing services, assay consumables, and analytical platforms.

A consortium of 14 pharmaceutical companies is funding analysis of the project’s first 300,000 samples. Their participation shows that protein information is gaining commercial value in drug-target selection, biomarker development, and treatment-response research.

Proteomics is positioned among the faster-growing multiomics platforms as pharmaceutical companies seek evidence that a potential drug target is active, measurable, and connected to disease progression. Suppliers that combine genetic and protein information within the same research environment can capture a larger share of pharmaceutical research spending.

 

Metabolomics Connects Biology with Environment and Lifestyle

Metabolomics measures small molecules created or changed by cellular activity. It is particularly relevant where researchers need to connect genetics with diet, medication, pollution, microbiome activity, or metabolic disease.

UK Biobank released metabolomics data covering approximately 500,000 participants in November 2025, expanding from an earlier dataset of around 300,000 people. Repeat samples from about 20,000 participants allow researchers to examine how metabolic patterns change over time.

Japan’s Tohoku Medical Megabank Organisation expanded the Japanese Multi-Omics Reference Panel in October 2025. Its updated resources include whole-genome analysis of 100,000 individuals and coverage approaching 900 metabolites.

These projects strengthen demand for population reference databases, long-term health analysis, laboratory services, and software that can connect metabolic findings with genomic and clinical information.

 

Mechanism-of-Action Analysis Expands Drug Discovery Opportunities

Multiomics pipelines combined with mechanism-of-action analysis bring together genomic, transcriptomic, proteomic, and metabolomic evidence to explain how a drug affects a biological system. Frameworks such as MultiOmicsIntegrator combine several datasets, while tools such as Open MoA connect drug-related changes with the proteins, pathways, and cellular functions most likely to be affected.

A typical study compares different doses and exposure periods in laboratory models. Researchers then examine changes in gene activity, proteins, and metabolites to determine whether a candidate produces the intended response.

The combined evidence can identify the drug’s likely main target, reveal possible secondary effects, and indicate which biological pathways have changed. Computer-based models may also estimate how changing a target could affect the wider cellular response.

Biomarker identification represents another commercially important output. Multiomics data can generate groups of markers indicating whether a drug reached its intended target, whether a patient is responding, and whether unwanted effects are developing. These findings support candidate selection, dose decisions, patient grouping, and clinical trial design.

Government-backed cancer research demonstrates the scale of this opportunity. The National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium has standardised genomic, protein, imaging, and clinical information from more than 1,000 tumors across 10 cancer types. Researchers use the resource to study disease pathways and identify possible treatment targets.

 

Government Research Pipeline and Approved Diagnostic Translation

Multiomics does not follow a conventional drug-approval pipeline because it is a research and analytical approach rather than a treatment. Its pipeline consists of government-funded population programs, biomarker studies, drug-target projects, and diagnostic research that may eventually support regulated tests or treatment-selection tools.

The NIH Multi-Omics for Health and Disease consortium represents one of the largest direct U.S. government commitments to this pipeline, with USD 50.3 million allocated over five years. The program creates opportunities for sequencing, protein analysis, metabolomics, sample processing, cloud infrastructure, and specialist research services.

The NCI’s cancer dataset adds genomic, protein, imaging, and clinical evidence from more than 1,000 tumors across 10 cancer types. This publicly available resource allows pharmaceutical companies, universities, and biotechnology firms to investigate possible targets, treatment resistance, and biomarker-led research programs without recreating the entire dataset independently.

On the approved side, multiomics findings generally reach the market through individual diagnostic tests rather than approval of an entire multiomics platform. In 2021, the FDA authorised 16 oncology-related in-vitro diagnostic devices, including 12 companion diagnostic approvals. These tests help determine whether patients are suitable for particular treatments.

The FDA’s companion-diagnostic list includes tests that measure selected genes, mutations, proteins, or imaging markers. Most approved products still focus on a defined marker rather than combining every biological layer within one test. Multiomics supports their development by helping researchers determine which markers are sufficiently reliable and clinically relevant to enter regulated diagnostic programs.

Government research funding therefore supports early discovery, while FDA-authorised diagnostics represent the later commercial route. Suppliers that help customers move from large research datasets to validated biomarkers and regulated laboratory tests can participate in both stages.

 

Single-Cell, Spatial, and Cloud Platforms Reshape Segmentation

Products, including instruments, consumables, and related research tools, accounted for approximately 58.3% of market revenue in 2025. Applied to SMR’s USD 3.25 billion valuation, this represents nearly USD 1.89 billion. Services accounted for the remaining 41.7%, equivalent to approximately USD 1.36 billion. Services are expected to expand faster as customers increasingly outsource sample processing, data integration, and specialist analysis.

By research format, bulk multiomics held approximately 70.1% of the market in 2025, representing nearly USD 2.28 billion. Its leadership reflects its suitability for large population studies and institutional research programs.

Single-cell multiomics accounted for the remaining 29.9%, equivalent to approximately USD 0.97 billion. Although smaller, the segment is projected to expand at approximately 17.84% CAGR as researchers seek more detailed information about individual cells and differences within the same tissue.

By application, oncology held approximately 41.5% of the Multiomics Market in 2025. Applied to SMR’s valuation, oncology generated an estimated USD 1.35 billion. The segment benefits from tumor profiling, biomarker discovery, drug-target validation, and treatment-response research.

Neurology is expected to grow at approximately 15.7% CAGR as researchers increasingly combine biological datasets to investigate complex neurological disorders and identify treatment targets. Immunology, metabolic disease, cardiovascular research, rare diseases, and population health provide additional demand.

By end user, academic and research institutes represented approximately 49.4% of market revenue in 2025, equivalent to nearly USD 1.61 billion. Their leadership reflects government-funded studies, university research, biobank programs, and large population projects.

Pharmaceutical and biotechnology companies represent the faster-growing end-user group because multiomics can influence target selection, clinical trial design, patient grouping, and biomarker development. Contract research organisations and specialist laboratories expand access for companies that do not own every required platform.

 

Competition Shifts Toward Integrated Portfolios

Competition is shifting away from standalone instruments toward integrated portfolios that combine sample preparation, biological measurement, data analysis, and cloud-based interpretation.

10x Genomics reported total revenue of USD 642.8 million in 2025, up 5% from USD 610.8 million in 2024. Excluding USD 44.1 million related to patent-litigation settlements, underlying revenue was approximately USD 598.7 million, representing a 2% decline from the previous year. These figures cover the company’s broader single-cell and spatial biology operations and should not be treated as revenue from the Multiomics Market alone.

Thermo Fisher Scientific completed its acquisition of Olink in July 2024 for approximately USD 3.1 billion. The transaction combined Olink’s protein-analysis portfolio with Thermo Fisher’s laboratory instruments, research services, global distribution network, and customer relationships.

Illumina completed its acquisition of SomaLogic in January 2026 for USD 350 million in cash, with up to USD 75 million in additional performance-based payments and royalties. The deal links SomaLogic’s protein-analysis capabilities with Illumina’s sequencing platforms, software, and wider multiomics strategy.

Illumina also introduced Connected Multiomics in January 2026, providing a cloud-based environment for analysing and visualising multiple biological data types. The platform was developed using feedback from 40 early-access users, while a later update added optional AI-assisted workflow recommendations.

Bruker acquired substantially all of NanoString’s business assets in May 2024 for approximately USD 392.6 million. The acquired operations generated around USD 168 million in 2023 and included the nCounter, GeoMx, CosMx, and AtoMx product lines.

These transactions show that major life-science companies are accelerating portfolio expansion by acquiring protein-analysis, spatial-biology, and software capabilities rather than relying entirely on internal development.

 

Regional Research Infrastructure Determines Adoption

North America

North America accounted for approximately 48.9% of the Multiomics Market in 2025, representing an estimated USD 1.59 billion based on SMR’s base-year valuation. The region’s leadership is supported by NIH funding, substantial pharmaceutical R&D budgets, established sequencing infrastructure, and the presence of major technology and platform providers.

Programs such as All of Us and the NIH Multi-Omics for Health and Disease Consortium are creating large, diverse datasets that sustain demand for sequencing, assays, data storage, software, and analytical services.

Clinical adoption continues to lag behind research use. Laboratories must demonstrate that multiomics-based tests deliver consistent, reliable, and clinically useful results before biomarkers can enter routine patient care. Although this lengthens development timelines, it creates opportunities for validation providers, regulated laboratories, and specialised diagnostic partners.

Europe

Europe benefits from established biobanks, publicly funded research networks, and strong participation from multinational pharmaceutical companies. UK Biobank combines whole-genome and metabolomics data from approximately 500,000 participants with protein data from more than 54,000 individuals.

The planned expansion to 600,000 protein measurements will increase demand for assays, computing capacity, data-management services, and external research support. It will also give pharmaceutical companies access to long-term evidence for identifying, evaluating, and validating potential drug targets..

Asia-Pacific

Asia-Pacific is expected to record the fastest regional growth, with an estimated CAGR of approximately 17.75% during the forecast period. Expansion is supported by government-funded sequencing programs, growing population databases, biotechnology investment, and demand for datasets representing Asian populations.

Japan’s jMorp program integrates genomic, metabolic, laboratory, and health data, while India has completed whole-genome sequencing of more than 10,000 individuals across major population groups.

India’s GenomeIndia repository contains raw sequencing data from 9,772 samples, covering approximately 700 terabytes, alongside usable health information from 9,330 samples. The supporting Indian Biological Data Centre provides four petabytes of parallel storage and dedicated computing capacity.

These programs create opportunities in sequencing services, secure data platforms, reference databases, cloud analysis, and research partnerships involving universities, hospitals, biotechnology companies, and global instrument suppliers.

 

Market Outlook: Value Moves from Data Generation to Interpretation

Future market expansion will rely less on producing new biological data and more on standardising, interpreting, and turning existing measurements into actionable insights for research and commercial use.

Data collected across different instruments and laboratories often contain missing values, incompatible formats, and variations caused by sample preparation, handling procedures, or operating conditions. Large-scale projects also require secure data storage, standardised documentation, specialised expertise, and significant computing resources.

These challenges are increasing demand for workflow software, quality-control platforms, data-management services, cloud infrastructure, and curated biological databases. Pharmaceutical and biotechnology companies are placing greater value on systems that connect laboratory findings with clinical information rather than producing isolated datasets with limited downstream use.

Consumables and services will remain important revenue sources because every additional sample must be prepared, tested, processed, stored, and analysed. Single-cell multiomics is expected to expand faster than bulk analysis, while oncology will remain the largest application area and neurology will offer a comparatively faster-growing research opportunity.

Clinical adoption will progress more gradually. Biomarkers must demonstrate reproducible performance, clinical utility, laboratory reliability, and relevance to payer decision-making before they can move from research programs into routine patient testing.

 

Multiomics Market Report Coverage Table

 

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 3.25 Billion
Revenue Forecast in 2032	USD 8.82 Billion
Overall Growth Rate	CAGR of 15.3% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Million, CAGR (2026–2032)
Segmentation	By Component, By Omics Combination, By Research Resolution, By Application, By End User, By Geography
By Component	Instruments, Consumables and Assay Kits, Software and Cloud Platforms, Databases, Research Services
By Omics Combination	Genomics–Transcriptomics, Proteogenomics, Transcriptomics–Proteomics, Genomics–Metabolomics, Integrated Multi-Layer Analysis
By Research Resolution	Bulk Multiomics, Single-Cell Multiomics, Spatial Multiomics
By Application	Oncology, Immunology, Neurological Disorders, Metabolic Diseases, Cardiovascular Research, Rare Diseases, Drug Discovery, Population Health
By End User	Pharmaceutical and Biotechnology Companies, Academic and Government Research Institutes, Hospitals and Clinical Laboratories, Biobanks, Contract Research Organizations
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Expanding government-funded multiomics and population-genomics programs, increasing pharmaceutical demand for biomarker and drug-target validation, rapid adoption of single-cell and spatial research platforms, growth of cloud-based biological data analysis, and rising integration of genomic, transcriptomic, proteomic, and metabolomic datasets
Customization Option	Available upon request